Edition:
United States

D Pharm Ltd (DPRM.TA)

DPRM.TA on Tel Aviv Stock Exchange

69.30ILa
10:23am EDT
Change (% chg)

0.00 (+0.00%)
Prev Close
69.30
Open
66.70
Day's High
69.30
Day's Low
66.70
Volume
121
Avg. Vol
3,400
52-wk High
235.00
52-wk Low
60.00

Latest Key Developments (Source: Significant Developments)

D Pharm Ltd receives final positive results from a pilot Phase 2 study
Thursday, 30 Jul 2015 08:00am EDT 

D Pharm Ltd:Receives final positive results from a pilot Phase 2 study.Clinical study exploring DP-b99 in patients with acute high-risk inflammation of the pancreas.Preclinical and clinical data indicate a favorable safety profile for DP-b99.  Full Article

D Pharm Ltd receives final report for its phase 2 clinical study of THR-18 in acute stroke patients treated with tPA
Thursday, 14 May 2015 07:00am EDT 

D Pharm Ltd:Has received final report for its Phase 2 clinical study of THR-18.Says THR-18 demonstrated statistically significant reductions in the incidence of intracranial hemorrhage (ICH), brain swelling (edema) and a satisfactory safety profile in stroke patients treated with tPA.Moreover, stroke recovery was improved 2-fold in patients receiving THR-18, as judged by clinical outcome measures, 30 days following stroke.study successfully defined the maximal tolerated and safe dose of THR-18 in AIS patients.Imaging data as assessed by CT (computed tomography) on day 2 following stroke and tPA treatment indicate that, in contrast to placebo group, no patients treated with THR-18 had an intracranial hemorrhage, (p=0.02).Similarly, 0.54 mg/kg of THR-18 reduced by more than twice the occurrence of brain edema (p<0.05).  Full Article

C-FDA approves IND for D Pharm Ltd's anti-epileptic drug, DP-VPA in China
Tuesday, 14 Apr 2015 08:00am EDT 

D Pharm Ltd:Has been notified by its co-development partner, Jiangsu Nhwa Pharmaceutical Co., Ltd. (Nhwa), that they received an approval letter from Chinese Food and Drug Administration (C-FDA).That allows clinical development of DP-VPA, through Phase 3, for epilepsy.Specific clinical protocols will be communicated to the C-FDA before the start of each new study.NHWA will begin with bridging safety study and then proceed with large dose-ranging Phase 2b clinical study in epilepsy patients.Prior to IND approval, DP-VPA was granted Fast Track status, designation designed to bring important new drugs which treat serious or life-threatening condition and fill an unmet medical need to patients earlier.  Full Article

More From Around the Web

No consensus analysis data available.